282 related articles for article (PubMed ID: 38424367)
41. Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy.
Mohanty A; Uthaman S; Park IK
Molecules; 2020 Sep; 25(19):. PubMed ID: 32977707
[TBL] [Abstract][Full Text] [Related]
42. Micro- and nanocarrier-mediated lung targeting.
Kurmi BD; Kayat J; Gajbhiye V; Tekade RK; Jain NK
Expert Opin Drug Deliv; 2010 Jul; 7(7):781-94. PubMed ID: 20560777
[TBL] [Abstract][Full Text] [Related]
43. Exploitation of lipid-polymeric matrices at nanoscale for drug delivery applications.
Sgorla D; Bunhak ÉJ; Cavalcanti OA; Fonte P; Sarmento B
Expert Opin Drug Deliv; 2016 Sep; 13(9):1301-9. PubMed ID: 27110648
[TBL] [Abstract][Full Text] [Related]
44. Nano-Therapeutics for the Lung: State-of-the-Art and Future Perspectives.
Iyer R; Hsia CC; Nguyen KT
Curr Pharm Des; 2015; 21(36):5233-44. PubMed ID: 26412358
[TBL] [Abstract][Full Text] [Related]
45. Insight on nano drug delivery systems with targeted therapy in treatment of oral cancer.
Vyas K; Rathod M; Patel MM
Nanomedicine; 2023 Apr; 49():102662. PubMed ID: 36746272
[TBL] [Abstract][Full Text] [Related]
46. Application of nanotechnology in drug delivery systems for respiratory diseases (Review).
Luo MX; Hua S; Shang QY
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760125
[TBL] [Abstract][Full Text] [Related]
47. Lipid-based nanocarriers for breast cancer treatment - comprehensive review.
Talluri SV; Kuppusamy G; Karri VV; Tummala S; Madhunapantula SV
Drug Deliv; 2016 May; 23(4):1291-305. PubMed ID: 26430913
[TBL] [Abstract][Full Text] [Related]
48. Nanocarrier Mediated Intranasal Drug Delivery Systems for the Management of Parkinsonism: A Review.
Kapoor A; Hafeez A; Kushwaha P
Curr Drug Deliv; 2024; 21(5):709-725. PubMed ID: 37365787
[TBL] [Abstract][Full Text] [Related]
49. A review of nanocarrier-mediated drug delivery systems for posterior segment eye disease: challenges analysis and recent advances.
Wang R; Gao Y; Liu A; Zhai G
J Drug Target; 2021 Aug; 29(7):687-702. PubMed ID: 33474998
[TBL] [Abstract][Full Text] [Related]
50. Transcending the Cutaneous Barrier Through Nanocarrier Exploration for Passive Delivery of Anti-hypertensive Drugs: A Critical Review.
Kumar L; Utreja P
Recent Pat Nanotechnol; 2020; 14(3):193-209. PubMed ID: 32427090
[TBL] [Abstract][Full Text] [Related]
51. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies.
Jyoti K; Kaur K; Pandey RS; Jain UK; Chandra R; Madan J
J Colloid Interface Sci; 2015 May; 445():219-230. PubMed ID: 25622047
[TBL] [Abstract][Full Text] [Related]
52. Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update.
Abdulbaqi IM; Assi RA; Yaghmur A; Darwis Y; Mohtar N; Parumasivam T; Saqallah FG; Wahab HA
Pharmaceuticals (Basel); 2021 Jul; 14(8):. PubMed ID: 34451824
[TBL] [Abstract][Full Text] [Related]
53. Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy.
Xia W; Tao Z; Zhu B; Zhang W; Liu C; Chen S; Song M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502028
[TBL] [Abstract][Full Text] [Related]
54. Receptor-targeted nanocarriers for therapeutic delivery to cancer.
Yu B; Tai HC; Xue W; Lee LJ; Lee RJ
Mol Membr Biol; 2010 Oct; 27(7):286-98. PubMed ID: 21028937
[TBL] [Abstract][Full Text] [Related]
55. Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.
Ngan CL; Asmawi AA
Drug Deliv Transl Res; 2018 Oct; 8(5):1527-1544. PubMed ID: 29881970
[TBL] [Abstract][Full Text] [Related]
56. Lipid-based nanocarriers for drug delivery and targeting: a patent survey of methods of production and characterization.
Carbone C; Cupri S; Leonardi A; Puglisi G; Pignatello R
Pharm Pat Anal; 2013 Sep; 2(5):665-77. PubMed ID: 24237173
[TBL] [Abstract][Full Text] [Related]
57. Alzheimer's Disease and its Related Dementia Types: A Review on Their Management
Siafaka PI; Mutlu G; Okur NÜ
Curr Alzheimer Res; 2020; 17(14):1239-1261. PubMed ID: 33602090
[TBL] [Abstract][Full Text] [Related]
58. Lipid-Based Nanocarriers for Targeted Gene Delivery in Lung Cancer Therapy: Exploring a Novel Therapeutic Paradigm.
Beigi A; Naghib SM; Matini A; Tajabadi M; Mozafari MR
Curr Gene Ther; 2024 May; ():. PubMed ID: 38778601
[TBL] [Abstract][Full Text] [Related]
59. Potential of Nanocarrier-Based Drug Delivery Systems for Brain Targeting: A Current Review of Literature.
Alotaibi BS; Buabeid M; Ibrahim NA; Kharaba ZJ; Ijaz M; Noreen S; Murtaza G
Int J Nanomedicine; 2021; 16():7517-7533. PubMed ID: 34795481
[TBL] [Abstract][Full Text] [Related]
60. Highlights in nanocarriers for the treatment against cervical cancer.
Medina-Alarcón KP; Voltan AR; Fonseca-Santos B; Moro IJ; de Oliveira Souza F; Chorilli M; Soares CP; Dos Santos AG; Mendes-Giannini MJS; Fusco-Almeida AM
Mater Sci Eng C Mater Biol Appl; 2017 Nov; 80():748-759. PubMed ID: 28866224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
